Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may shed light on painful fat disorder

NCT ID NCT07651813

Knowledge-focused Sponsor: Kanuni Sultan Suleyman Training and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study investigates whether a natural molecule called Maresin-1, which helps reduce inflammation, is linked to lipedema—a chronic condition causing painful fat buildup in women. Researchers will measure Maresin-1 levels in the blood of women with lipedema, women with obesity but no lipedema, and healthy women. The goal is to see if Maresin-1 could serve as a biomarker to better understand or diagnose this poorly understood disorder.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If Maresin-1 levels differ between groups, it could point toward a simple blood test to help diagnose or monitor lipedema.
What could go wrong
This is a small observational study, not a treatment trial. It may find no meaningful differences, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jun 2026

An estimate. Start dates often move.

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of adult women aged 18 to 65 years recruited from the Physical Medicine and Rehabilitation outpatient clinic of a tertiary care hospital. Participants will be classified into three groups: (1) women with clinically diagnosed lipedema, (2) women with obesity (body mass index ≥30 kg/m²) without lipedema, and (3) healthy female volunteers without chronic or inflammatory diseases. A total of 84 participants are planned to be enrolled, with 28 individuals in each group. The study aims to compare serum Maresin-1 levels and their associations with clinical and inflammatory parameters across these populations.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female participants aged 18 to 65 years. Women with a clinical diagnosis of lipedema for the lipedema group. Women with obesity (body mass index ≥30 kg/m²) and without a diagnosis of lipedema for the obesity group. Healthy female volunteers without chronic or inflammatory diseases for the healthy control group. No acute infection within the previous 3 months. Ability and willingness to provide written informed consent. Exclusion Criteria: * Active infection at the time of enrollment. History of autoimmune or chronic inflammatory disease. History of malignancy. Pregnancy or breastfeeding. Current use of corticosteroids or immunosuppressive medications. Regular use of anti-inflammatory medications that may affect inflammatory biomarkers. Acute infection within the previous 3 months. Inability to comply with study procedures or complete study assessments. Refusal or inability to provide written informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lipedema are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lipedema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lipedema

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.